Go Pro
NASDAQ:FENC

Adherex Technologies Q2 2026 Earnings Report

Adherex Technologies logo
$11.57 +0.73 (+6.73%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$11.58 +0.02 (+0.13%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adherex Technologies EPS Results

Actual EPS
N/A
Consensus EPS
$0.02
Beat/Miss
N/A
One Year Ago EPS
N/A

Adherex Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$16.21 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adherex Technologies Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Adherex Technologies Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
Fennec Announces Results of Annual Meeting
See More Adherex Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies (NASDAQ:FENC) and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

View Adherex Technologies Profile